5 B), and the survival rate until day 50 showed a trend of improvement in mice treated with CVA11 compared with untreated mice (Fig. 5 C), illustrating the tolerability of CVA11 therapy.
← all excerpts
Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer.
1
—
—